SG11201906321WA - Novel process for preparing water soluble forskolin - Google Patents
Novel process for preparing water soluble forskolinInfo
- Publication number
- SG11201906321WA SG11201906321WA SG11201906321WA SG11201906321WA SG11201906321WA SG 11201906321W A SG11201906321W A SG 11201906321WA SG 11201906321W A SG11201906321W A SG 11201906321WA SG 11201906321W A SG11201906321W A SG 11201906321WA SG 11201906321W A SG11201906321W A SG 11201906321WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- forskolin
- pct
- water soluble
- novel process
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17150644 | 2017-01-09 | ||
| PCT/EP2018/050447 WO2018127600A1 (en) | 2017-01-09 | 2018-01-09 | Novel process for preparing water soluble forskolin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906321WA true SG11201906321WA (en) | 2019-08-27 |
Family
ID=57868023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906321WA SG11201906321WA (en) | 2017-01-09 | 2018-01-09 | Novel process for preparing water soluble forskolin |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11234957B2 (da) |
| EP (1) | EP3565602B1 (da) |
| JP (1) | JP7138643B2 (da) |
| KR (1) | KR102583356B1 (da) |
| CN (1) | CN110325217B (da) |
| CY (1) | CY1124325T1 (da) |
| DK (1) | DK3565602T3 (da) |
| ES (1) | ES2872223T3 (da) |
| HR (1) | HRP20210863T1 (da) |
| HU (1) | HUE054617T2 (da) |
| LT (1) | LT3565602T (da) |
| PL (1) | PL3565602T3 (da) |
| PT (1) | PT3565602T (da) |
| RS (1) | RS61915B1 (da) |
| SG (1) | SG11201906321WA (da) |
| SI (1) | SI3565602T1 (da) |
| WO (1) | WO2018127600A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4093374T3 (en) | 2020-01-23 | 2024-02-06 | Scipharm S A R L | A complex consisting of 7-deacetylforskolin and PVP |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU199444B (en) | 1985-09-10 | 1990-02-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom |
| JP3040015B2 (ja) * | 1991-08-21 | 2000-05-08 | 日研化学株式会社 | フォルスコリンの包接化合物 |
| IT1294205B1 (it) | 1997-07-23 | 1999-03-24 | Farmigea Spa | Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive |
| US6884885B2 (en) * | 2000-12-21 | 2005-04-26 | Cerestar Holding B.V. | Production of cyclodextrin complexes |
| GB0127677D0 (en) * | 2001-11-19 | 2002-01-09 | Vianex S A | Inclusion complex |
| JP4982656B2 (ja) | 2003-05-20 | 2012-07-25 | 東洋精糖株式会社 | 水可溶性イソフラボン組成物およびその製造方法並びにその用途 |
| US6960300B2 (en) | 2003-09-08 | 2005-11-01 | Sami Labs Limited | Process for preparing water soluble diterpenes and their applications |
| PT1793862E (pt) * | 2004-08-02 | 2011-04-08 | Chiesi Farma Spa | Processo para a preparação de um composto de inclusão de piroxicam:beta-ciclodextrina |
| BRPI0705319A2 (pt) * | 2007-07-23 | 2009-07-21 | Uniao Brasileira De Educacao Manedora Da Pucrs | processo para obtenção de um complexo solúvel de resveratrol e/ou seus derivados; complexo de resveratrol e/ou seus derivados; composição nutracêutica |
| EP2253627A1 (en) | 2009-05-21 | 2010-11-24 | ERREGIERRE S.p.A. | Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin. |
| CN103768616B (zh) * | 2014-01-08 | 2015-08-05 | 中国科学院昆明植物研究所 | 毛萼乙素环糊精包合物、含有该包合物的药物组合物、其制备方法及应用 |
-
2018
- 2018-01-09 SG SG11201906321WA patent/SG11201906321WA/en unknown
- 2018-01-09 KR KR1020197023146A patent/KR102583356B1/ko active IP Right Grant
- 2018-01-09 SI SI201830296T patent/SI3565602T1/sl unknown
- 2018-01-09 JP JP2019537301A patent/JP7138643B2/ja active Active
- 2018-01-09 HU HUE18700143A patent/HUE054617T2/hu unknown
- 2018-01-09 US US16/476,337 patent/US11234957B2/en active Active
- 2018-01-09 LT LTEP18700143.3T patent/LT3565602T/lt unknown
- 2018-01-09 WO PCT/EP2018/050447 patent/WO2018127600A1/en active Application Filing
- 2018-01-09 DK DK18700143.3T patent/DK3565602T3/da active
- 2018-01-09 PT PT187001433T patent/PT3565602T/pt unknown
- 2018-01-09 RS RS20210673A patent/RS61915B1/sr unknown
- 2018-01-09 CN CN201880013198.3A patent/CN110325217B/zh active Active
- 2018-01-09 PL PL18700143T patent/PL3565602T3/pl unknown
- 2018-01-09 EP EP18700143.3A patent/EP3565602B1/en active Active
- 2018-01-09 ES ES18700143T patent/ES2872223T3/es active Active
-
2021
- 2021-05-31 HR HRP20210863TT patent/HRP20210863T1/hr unknown
- 2021-06-01 CY CY20211100478T patent/CY1124325T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1124325T1 (el) | 2022-07-22 |
| WO2018127600A1 (en) | 2018-07-12 |
| KR102583356B1 (ko) | 2023-09-26 |
| US11234957B2 (en) | 2022-02-01 |
| SI3565602T1 (sl) | 2021-07-30 |
| PL3565602T3 (pl) | 2021-09-13 |
| CN110325217A (zh) | 2019-10-11 |
| JP7138643B2 (ja) | 2022-09-16 |
| JP2020505339A (ja) | 2020-02-20 |
| EP3565602A1 (en) | 2019-11-13 |
| HUE054617T2 (hu) | 2021-09-28 |
| KR20190107690A (ko) | 2019-09-20 |
| ES2872223T3 (es) | 2021-11-02 |
| CN110325217B (zh) | 2023-08-08 |
| PT3565602T (pt) | 2021-05-26 |
| LT3565602T (lt) | 2021-06-25 |
| US20210145791A1 (en) | 2021-05-20 |
| EP3565602B1 (en) | 2021-03-03 |
| DK3565602T3 (da) | 2021-06-07 |
| HRP20210863T1 (hr) | 2021-08-20 |
| RS61915B1 (sr) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
| SG11201807185UA (en) | Modified hyaluronic acid, method for making same and uses thereof | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201806538WA (en) | Engineered antigen presenting cells and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers |